Claims
- 1. A biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAs nSerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
- 2. A biologically active peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAs nSerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31 )NH2 or desamino Ser1 hPTH(1-34)NH2.
- 3. The peptide of claim 1 which is:
Desamino-AlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSer MetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:5).
- 4. The peptide of claim 1 which is:
Desamino-GlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSer MetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:2).
- 5. The peptide of claim 1 wherein the peptide is labeled with a label selected from the group consisting of: radiolabel, flourescent label, bioluminescent label, or chemiluminescent label.
- 6. The peptide of claim 5, wherein said radiolabel is 99mTc.
- 7. A pharmaceutical composition comprising
(a) a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly; and a pharmaceutically acceptable carrier.
- 8. A pharmaceutical composition comprising
(a) a biologically active peptide consisting essentially of the formula:
X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly; and a pharmaceutically acceptable carrier.
- 9. A nucleic acid molecule consisting essentially of a polynucleotide encoding a biologically active peptide which has an amino acid sequence selected from the group consisting of:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
- 10. A recombinant DNA molecule comprising: (1) an expression control region, said region in operable linkage with (2) a polynucleotide sequence coding for a biologically active peptide, wherein said peptide is selected from the group consisting of:
(a) X01 ValSerGluIleGInLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
- 11. A method of preparing a biologically active peptide comprising introducing into a host the recombinant DNA molecule of claim 9, and causing expression of said molecule.
- 12. A method for making a recombinant vector comprising inserting a nucleic acid molecule of claim 8 into a vector.
- 13. The recombinant DNA molecule of claim 9, wherein said control region includes a bacterial, viral, fungal or mammalian promoter.
- 14. A host cell containing the recombinant DNA molecule of claim 9.
- 15. The cell of claim 13 which is prokaryotic.
- 16. The cell of claim 14 which is bacterial.
- 17. The cell of claim 13 which is eukaryotic.
- 18. The cell of claim 16 which is a yeast cell or a mammalian cell.
- 19. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass-increasing amount of a biologically active peptide, wherein said peptide comprises an amino acid sequence at least 90% identical to a member selected from the group consisting essentially of:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2; and a pharmaceutically acceptable carrier.
- 20. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass-increasing amount of a biologically active peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1); (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2; and a pharmaceutically acceptable carrier.
- 21. A method for determining rates of bone reformation, bone resorption and/or bone remodeling comprising administering to a patient an effective amount of a peptide of claim 4 and determining the uptake of said peptide into the bone of said patient.
- 22. The method of claim 19, wherein said effective bone mass-increasing amount of said peptide is administered by providing to the patient DNA encoding said peptide and expressing said peptide in vivo.
- 23. A method of claim 19, wherein the condition to be treated is osteoporosis.
- 24. A method of claim 19, wherein said osteoporosis is old age osteoporosis.
- 25. A method of claim 19, wherein said osteoporosis is post-menopausal osteoporosis.
- 26. A method of claim 19, wherein the effective amount of said peptide for increasing bone mass is from about 0.01 μg/kg/day to about 1.0 μg/kg/day.
- 27. The method of claim 19, wherein the method of administration is parenteral.
- 28. The method of claim 19, wherein the method of administration is subcutaneous.
- 29. The method of claim 19, wherein the method of administration is nasal insufflation.
Parent Case Info
[0001] This application claims the benefit of the filing date of provisional application No. 60/110,152 filed on Nov. 25, 1998, which is herein incorporated by reference.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT
[0002] Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government has certain rights in this invention.
[0003] This work was supported by National Institutes of Health Grant DK 1 1794.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60110152 |
Nov 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09447800 |
Nov 1999 |
US |
Child |
10361928 |
Feb 2003 |
US |